MediPharm Labs Corp. (FRA:MLZ)
Germany · Delayed Price · Currency is EUR 0.0396
-0.0002 (-0.50%)
At close: Jan 23, 2026
MediPharm Labs Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 46.1 | 41.96 | 33.06 | 22.12 | 21.71 | 36.01 | |
Revenue Growth (YoY) | 18.06% | 26.92% | 49.49% | 1.87% | -39.71% | -72.14% |
Cost of Revenue | 32.14 | 28.42 | 24.96 | 24.19 | 35.13 | 74.88 |
Gross Profit | 13.96 | 13.54 | 8.1 | -2.07 | -13.42 | -38.86 |
Selling, General & Admin | 20.65 | 22.05 | 21.07 | 24.4 | 30.87 | 27.81 |
Research & Development | 0.23 | 0.32 | 0.29 | 1.12 | 1.51 | 2.21 |
Other Operating Expenses | -0.35 | -0.07 | 0.07 | 0.17 | -0.07 | 0.53 |
Operating Expenses | 20.54 | 22.3 | 21.42 | 25.7 | 32.3 | 30.55 |
Operating Income | -6.58 | -8.76 | -13.32 | -27.77 | -45.72 | -69.41 |
Interest Expense | -0.07 | -0.58 | -0.37 | -0.03 | -10.51 | -7.88 |
Interest & Investment Income | 0.27 | 0.69 | 0.84 | 0.48 | 0.23 | 0.27 |
Currency Exchange Gain (Loss) | 0.06 | 0.06 | -0.46 | -0.74 | -1.67 | 1.18 |
Other Non Operating Income (Expenses) | - | - | - | 0 | 4.51 | 8.08 |
EBT Excluding Unusual Items | -6.32 | -8.59 | -13.3 | -28.06 | -53.16 | -67.76 |
Merger & Restructuring Charges | -1.3 | -1.81 | -4.42 | -1.04 | - | -1.25 |
Gain (Loss) on Sale of Assets | -0.3 | -0.3 | -0.08 | -0.91 | - | - |
Asset Writedown | -0.12 | - | -0.22 | - | -6.29 | -7.6 |
Other Unusual Items | - | - | 4.67 | 0.02 | 4.76 | 4.51 |
Pretax Income | -8.03 | -10.69 | -13.36 | -29.99 | -54.69 | -72.1 |
Income Tax Expense | - | - | -0.28 | -0.01 | 0.11 | -4.99 |
Earnings From Continuing Operations | -8.03 | -10.69 | -13.08 | -29.98 | -54.8 | -67.11 |
Minority Interest in Earnings | - | - | - | - | - | 0.76 |
Net Income | -8.03 | -10.69 | -13.08 | -29.98 | -54.8 | -66.35 |
Net Income to Common | -8.03 | -10.69 | -13.08 | -29.98 | -54.8 | -66.35 |
Shares Outstanding (Basic) | 416 | 408 | 363 | 277 | 250 | 139 |
Shares Outstanding (Diluted) | 416 | 408 | 363 | 277 | 250 | 139 |
Shares Change (YoY) | 4.10% | 12.29% | 31.23% | 10.79% | 80.37% | 2.91% |
EPS (Basic) | -0.02 | -0.03 | -0.04 | -0.11 | -0.22 | -0.48 |
EPS (Diluted) | -0.02 | -0.03 | -0.04 | -0.11 | -0.22 | -0.48 |
Free Cash Flow | -7.15 | -5.02 | -12.81 | -16.93 | -14 | -45.28 |
Free Cash Flow Per Share | -0.02 | -0.01 | -0.04 | -0.06 | -0.06 | -0.33 |
Gross Margin | 30.28% | 32.26% | 24.50% | -9.38% | -61.81% | -107.92% |
Operating Margin | -14.27% | -20.88% | -40.30% | -125.56% | -210.59% | -192.75% |
Profit Margin | -17.41% | -25.49% | -39.57% | -135.56% | -252.41% | -184.25% |
Free Cash Flow Margin | -15.51% | -11.95% | -38.75% | -76.56% | -64.46% | -125.72% |
EBITDA | -4.84 | -6.23 | -10.92 | -24.99 | -40.42 | -59.03 |
EBITDA Margin | -10.50% | -14.84% | -33.02% | -112.99% | -186.17% | -163.91% |
D&A For EBITDA | 1.73 | 2.54 | 2.41 | 2.78 | 5.3 | 10.39 |
EBIT | -6.58 | -8.76 | -13.32 | -27.77 | -45.72 | -69.41 |
EBIT Margin | -14.27% | -20.88% | -40.30% | -125.56% | -210.59% | -192.75% |
Revenue as Reported | 46.1 | 41.96 | 33.06 | 22.12 | - | - |
Advertising Expenses | - | 0.87 | 1.27 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.